The board of directors at Whitehawk Therapeutics consists of experienced life sciences executives and healthcare investors who guide the company's corporate governance and clinical development strategies. Key members include Dr. Dave Lennon, who serves as President, CEO, and board director, alongside independent and venture-backed directors such as Dr. Caley Castelein, representing healthcare investment leadership from Kearny Venture Partners, who bring deep expertise in oncology commercialization, capital allocation, and biotechnology governance.